Wolfgang Miesbach: Cognitive Impairment in aPL-Positive Patients
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Cognitive impairment in aPL-positive patients.
An important presentation by Gustavo Balbi and colleagues on the real-world recognition and management of cognitive impairment in patients with antiphospholipid antibodies (aPL).
Clinicians most frequently associated aPL with depression, anxiety, impaired attention, slower processing speed, and memory or executive dysfunction.
Yet routine cognitive screening remains uncommon – particularly in patients without stroke and TIA or overt symptoms.
Stronger collaboration between APS specialists, cognitive neurologists, and neuropsychologists is urgently needed to improve recognition, assessment, and care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation